Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Cervical Cancer Prevention Month

In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer

Innovative Trials

- PMLiVE

AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients

The phase 3 trial results for patients diagnosed with first-line unresectable liver cancer showed a 31% survival rate after three years

- PMLiVE

Almirall and IRB Barcelona announce new research collaboration

The two companies will work together to discover new therapies for chronic skin diseases

- PMLiVE

6 critical success factors for flawless execution of a rapid first commercial launch

Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline.

Avalere Health

- PMLiVE

Meet Innovative Trials at SCOPE 2022

Stop by Booth 1015 to meet the Innovative Trials' team during SCOPE 2022

Innovative Trials

We let your whole self shine

People are at the heart of who we are. Our aim is to transform the lives of those we touch without prejudice or discrimination. At Lucid, the magic we create...

Lucid Group Communications Limited

EU flag

EMA proposes EU clinical trial reforms

The ACT EU paper provides a list of regulatory network objectives, priorities and governance strategies for 2022-2023

Anthem PR appoints new managing director Rebecca Fergusson

Fergusson previously held senior leadership positions at Mind + Matter and Red Health

image of scales

Hybrid working: Insights and tips for success

Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success

Porterhouse Medical Group

- PMLiVE

AstraZeneca’s Enhertu receives FDA grant for priority review

The approval is based on results from the DESTINY-Breast03 trial which showed a significant risk reduction of unresectable or metastatic HER-2 positive breast cancer progression

- PMLiVE

Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis

The FDA based its approval on results from a clinical trial programme involving over 1,600 patients

- PMLiVE

Vir Biotech launches new research programme for HIV and malaria prevention

Using antibody research, Vir will combine its existing immunology and virology expertise with the Gates Foundation

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links